Life Science companies are growing globally to increase revenue. To maximize profitability and increase shareholder value, they are forced to maximize tax effectiveness. The US Government (with a non competitive corporate tax structure) is deeming this process as negative. In fact, the Life Science Industry is forced to leverage and effectively manage tax to drive shareholder value. Increase in shareholder value provides tax revenue from increase stock price and dividend growth.